Thymus gland may hold key to preventing immune cell loss during lung cancer treatment
NCT ID NCT07564089
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the size and shape of the thymus gland, along with the radiation dose it receives, can predict a drop in immune cells (lymphocytes) during chest radiation for stage III lung cancer. Researchers will collect data from standard scans and blood tests of 450 adults receiving curative radiation, without changing their treatment. The goal is to find ways to design radiation plans that spare the immune system in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could help doctors design radiation treatments that better protect the immune system, potentially reducing side effects for future lung cancer patients.
What could go wrong
This is an observational study, so it does not test a new treatment. The findings may not lead to immediate changes in care, and results might not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- PulmoPrint: Fluorescence Bronchoscopy in Lung Ca NCT07653438
- PD-1 Knockout TIL Therapy for Melanoma & Lung Ca NCT05361174
- Durvalumab + SBRT for Stage III Lung Cancer (NCT03589547)
- ARTIA-Lung Trial: Reducing Side Effects in Lung NCT05488626
- PACCELIO Trial: New Chemo-Radiation for Lung Can NCT06102057
- NSCLC Trial: ctDNA-Guided Cemiplimab & Chemo (NCT06917573)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330000, China